Digital Therapeutics (DTx)

Online Roundtable Discussion Among Clinical Doctors 【Part 6】

This issue will be the last “Sleep and Sleep Tech” online roundtable discussion with clinical doctors, attended by doctors interested in the current focus on “sleep tech.”　The topic will evolve into implementing apps in the medical field, cognitive behavioral therapy, and more. 

Alcoholism and the Development of Therapeutic Apps

CureApp Inc.’s therapeutic app for alcohol dependence began clinical trials in Japan in January 2023. Dr. Amano focuses on the app and explains alcoholism and therapeutic apps from a psychiatrist’s perspective.

The Second Part: Brief Cognitive Function Assessment Scale in Middle Age and Beyond “The MCI Screen (Atama no Kenko Check)”

In the previous article, we provided an overview of “The MCI Screen (Atama no Kenko Check)” as a cognitive function scale is expected to detect mild cognitive impairment (MCI) at an early stage. In the second part of issue, Dr. Y, a psychiatrist, will explain the specifics of the system and examples of its use in clinical research.

The First Part: Brief Cognitive Function Assessment Scale in Middle Age and Beyond “The MCI Screen (Atama no Kenko Check)”

It is said that “prevention” of dementia is the key to early detection and intervention to delay the onset of the disease. The “The MCI Screen (Atama no Kenko Check),” a cognitive function scale for healthy people with no complaints of cognitive decline, is expected to be useful for the early detection of mild cognitive impairment (MCI). Dr. Y, a psychiatrist, will explain this assessment scale in detail.

Online Roundtable Discussion Among Clinical Doctors 【Part 5】

Continuing from the previous meeting, doctors interested in “Sleep Tech” will gather to discuss “Sleep and Sleep Tech” frankly. This time, they will discuss topics such as smart rings and mindfulness.

Online Roundtable Discussion Among Clinical Doctors 【Part 4】

Doctors interested in “Sleep Tech,” which has been the focus of much attention in recent years, were invited to gather to discuss “How does Sleep Tech work?” They will also talk about the effects and impressions of using it and ask each other about sleep-related topics. The content of this session is a casual read about “Sleep and Sleep Tech.” In this issue, we present the first of three roundtable discussions.

The Second Part: Tapping into the Challenges of Diabetes and Lifestyle Management, Health2Sync

“Health2Sync,” provided by H2 Inc, a Taiwan-based health tech company, is the first application in Japan that can be linked to CGM data from Abbott Japan devices. Continuing from the first part, Dr. Amano, a diabetes specialist, will explain the details.

The Second Part: Apps and Wearable Devices in Sleep

Japan beginning in FY2022, the introduction of therapeutic apps in medicine is expected to gain momentum. Dr. Amano will discuss the expectations and challenges of introducing therapeutic apps for insomnia treatment from a psychiatrist's perspective.

The First Part: Tapping into the Challenges of Diabetes and Lifestyle Management, Health2Sync

Health2Sync, which aims to support people's health with the “power of digital,” provides “Health2Sync,” a healthy lifestyle support application for self-management of chronic diseases such as diabetes, and “Health2Sync Platform,” a cloud service that enables medical institutions to view the data of the application. Ono M.D., a diabetes specialist, will explain these services.

The first part: Apps and Wearable Devices in Sleep

This is a new series in which Dr. Amano, a psychiatrist, and occupational health physician will explain the “Utilization of Digital Technology in Mental Health and Psychiatry” from her knowledge as a specialist. The content of this first issue is “The first part: Apps and Wearable Devices in Sleep.”

The Second Part: TechDoctor Moving Toward an Era Where Data Improves “Wellness”

TechDoctor announced in June of this year that it had raised 500 million Japanese yen in a Series A round. We will explain the company's technology, focusing on an interview with Kazushu Minato, CEO of TechDoctor, a fast-growing medical data analysis startup.

The First Part: TechDoctor Moving Toward an Era Where Data Improves “Wellness”

Digital biomarkers, which can acquire and analyze data that is difficult to obtain with conventional biomarkers, can contribute to shorter time to diagnosis and earlier treatment. The “SelfDoc.” wearable outpatient solution for psychiatry and the “SelfBase” medical data analysis platform developed by TechDoctor, Inc. which is involved in the development of digital biomarkers will be explained.

Online Roundtable Discussion Among Clinical Doctors 【Part 3】

This is the third and final part of the Online Roundtable Discussion Among Clinical Doctors on “About the Ongoing Application of Digital Technology in the Medical Field.” We will ask slightly different questions to doctors about their honest opinions about digital health.

Online Roundtable Discussion Among Clinical Doctors 【Part 2】

We are pleased to present the second part of the Online Roundtable Discussion Among Clinical Doctors, in which they share their views on the current state of digital health and what they expect in the future. This time, we asked questions about the content of the previous roundtable discussion. The following is a frank discussion by three clinical doctors on these questions.

Online Roundtable Discussion Among Clinical Doctors 【Part 1】

In recent years, digital transformation has been expected to advance in various fields, but how much digitalization is taking place in the medical field? How far has digitalization progressed in the medical field, and what are people in the medical field thinking about digital health? The topic of this meeting is “About the Ongoing Application of Digital Technology in the Medical Field.” The content of this roundtable will be divided into three parts.

Current Status of Digital Therapeutics for Mild Cognitive Impairment

The number of patients with Alzheimer's disease (AD) is increasing, and digital therapeutics (DTx) for AD treatment is the focus of much attention. In the U.S., there are some startups that are supported by colossal research funds for research on screening for mild cognitive impairment (MCI). Dr. Y will explain the future of MCI treatment and DTx from the perspective of an active psychiatrist.

Digital Screening for Cognitive Impairment

With the FDA approval of Aducanumab for the treatment of Alzheimer's disease, how will it affect future treatments? Dr. Y, a psychiatrist, explains his views on this issue, including expectations for digital therapeutics to identify mild cognitive impairment (MCI).

The Impact of Changes in the COVID19 Pandemic on Psychiatry

Expectations for digital tools
In this new series of columns, an psychiatrist in Japan talks about the potential of digital tools in psychiatry. In this first part of a series, we present the expectations for digital tools for psychiatry in the COVID-19 Pandemic.

CureApp SC, the first Nicotine Addiction Therapeutics App receives regulatory approval in Japan

Nicotine Addiction treatment realizes telemedicine and digital healt

Dr. Shinpaku, an internist specializing in respiratory medicine and infectious diseases, writes a new series of columns featuring innovative technologies from Japanese startups. In the first of the series, he focuses on CureApp's Nicotine Addiction Therapeutics App.